Clinical Trial Update: A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating CCR4-directed CAR T cells in CCR4-expressing mature T-cell malignancies, including peripheral T-cell lymphoma and cutaneo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Cutaneous T-cell Lymphoma
• Enteropathy-associated T-cell Lymphoma
• Hepatosplenic T-cell Lymphoma
• Monomorphic Epitheliotropic Intestinal Lymphoma
• Mycosis Fungoides
• Peripheral T-cell Lymphoma

Drugs mentioned

• CCR4 CAR T cells

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma | Phase 1 | Status: RECRUITING